MedTrace Logo

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-63623872 in Healthy Japanese Adult Participants

NCT02418559 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2015-09-22

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of JNJ-63623872 following oral administration of single ascending dose of JNJ-63623872 in healthy Japanese adult participants.

Conditions

  • Healthy

Interventions

DRUG

JNJ-63623872 (300 mg)

Participants will receive JNJ-63623872 300 mg tablet orally once on Day 1 under fasted conditions.

DRUG

JNJ-63623872 (600 mg)

Participants will receive JNJ-63623872 600 mg (2\*300 mg) tablet orally once on Day 1 under fasted conditions.

DRUG

JNJ-63623872 (1200 mg)

Participants will receive JNJ-63623872 1200 mg (4\*300 mg) tablet orally once on Day 1 under fasted conditions.

DRUG

Placebo

Participants will receive placebo tablet orally once on Day 1 under fasted conditions.

Sponsors & Collaborators

  • Janssen Infectious Diseases BVBA

    lead INDUSTRY

Principal Investigators

  • Janssen Infectious Diseases BVBA Clinical Trial · Janssen Infectious Diseases BVBA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2015-07-31
Completion
2015-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02418559 on ClinicalTrials.gov